Study of a single dose of BL0175 in postmenopausal women
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This trial tests a single injection of BL0175 in postmenopausal women to see how the body processes it and whether it is safe. It may help if you are looking for new treatment options for certain conditions in postmenopausal women.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause (no periods for at least 12 months or had your ovaries removed) and are 18 years or older
- You weigh at least 45 kg (about 99 lbs) and your body mass index (BMI) is between 18 and 35
- You do not have any serious medical conditions like heart, liver, kidney, or nerve disease
- You are not allergic to fulvestrant, alcohol, castor oil, or similar substances
- You have not had an organ or stem cell transplant, and do not have active infections like hepatitis B, C, or HIV
- You are willing to avoid alcohol, strenuous exercise, and certain medications for a period before and during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe and tolerable a new drug, KSHN001034, is in healthy women who have gone through menopause. It involves multiple doses to see how your body processes the medicine.
This trial tests a new drug called BL0175 to see if it helps postmenopausal women with advanced breast cancer that has stopped responding to hormone therapy. The drug is given as an injection, and the study compares different doses to find the safest and most effective one.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a new oral medicine combined with a standard hormone therapy for advanced hormone-receptor-positive, HER2-negative breast cancer. The goal is to see if the combination can help control the cancer better than hormone therapy alone.
Hear when a new Postmenopausal Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.